US Bioservices selected by AstraZeneca to dispense IRESSA and TAGRISSO

February 06, 2017


Frisco, Texas – US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, announced today it has been selected by AstraZeneca to dispense IRESSA® (gefitinib) and TAGRISSO® (osimertinib) for the treatment of advanced non-small cell lung cancer in patients whose tumors foster gene mutations.

IRESSA was approved by the U.S. Food and Drug Administration on July 13, 2015 for the first-line treatment of patients with metastatic non-small cell lung cancer (NS